Inogen, Inc. INGN
5.73 USD -0.27 (-4.50%)
Nov 11, 2026, 3:24 PM EST
5.69 Day range 6.01
5.05 52-week range 7.67
- YTD
- -14.73%
- 1 year
- -18.03%
- Market cap
- 148.99M
- Revenue (ttm)
- 331.52M
- Profit margin
- -15.89%
- EPS (ttm)
- -1.21
- Shares out
- 23.82M
- Forward P/E
- -5.44
- YTD return
- -14.73%
- 1-year return
- -18.03%
- Volume
- 188.75K
- Avg volume
- 312.02K
- Open
- 6.00
- Previous close
- 6.00
- Day's range
- 5.69 – 6.01
- 52-week range
- 5.05 – 7.67
- Beta
- 1.04
- Analysts
- Hold
- Price target
- 10.00 (+74.5%)
5D -1.39 (-18.81%)
Key statistics
- Enterprise value
- 101.46M
- PEG ratio
- 0.00
- Price / sales
- 0.61
- Price / book
- 1.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 5.80%
- Free cash flow
- 2.52M
- Total cash
- 120.66M
- Total debt
- 20.15M
- Return on equity
- -25.33%
- Short % of float
- 3.35%
- 50-day average
- 9.45
- 200-day average
- 9.07
Analyst view
Consensus: hold
Hold
Price target (mean) 10.00
Ratings (0m) 4 1 buy · 2 hold · 1 sell
- Strong buy0
- Buy1
- Hold2
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate -0.49.
Financials — quick view
INGN Revenue — quarterly 77.19M
INGN Net income — quarterly -16.16M
INGN EPS — quarterly -0.61
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.51 | -0.25 | +0.26 | +50.98% |
| Aug 6, 2024 | Jun 1, 2024 | -0.54 | -0.24 | +0.30 | +55.56% |
| May 7, 2024 | Mar 1, 2024 | -0.76 | -0.62 | +0.14 | +18.42% |
| Feb 27, 2024 | Dec 1, 2023 | -0.65 | -1.14 | -0.49 | -75.38% |
| Nov 7, 2023 | Sep 1, 2023 | -0.57 | -1.97 | -1.40 | -245.61% |
| Aug 7, 2023 | Jun 1, 2023 | -0.64 | -0.42 | +0.22 | +34.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | Needham | reit | — | Hold |
| Aug 7, 2024 | Needham | reit | — | Hold |
| May 8, 2024 | Stifel | main | Hold | Hold |
| May 8, 2024 | Needham | reit | — | Hold |
| Apr 9, 2024 | Needham | reit | — | Hold |
| Feb 15, 2024 | William Blair | up | Market Perform | Outperform |
About Inogen, Inc.
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- inogen.com
News
Inogen, Inc. (INGN) Q3 2026 Earnings Call Transcript 
What Inogen (INGN) Said on Its Q3 Earnings Call 
Inogen Q3 2026 Earnings Call Transcript 
Inogen Lowers FY2026 Sales Guidance from $355.000M-$361.000M to $298.000M-$301.000M vs $356.400M Est 
UPDATED: Inogen Q3 Adj. EPS $(0.02) Beats $(0.14) Estimate, Sales $77.193M Miss $92.250M Estimate 
Inogen Announces Third Quarter 2026 Financial Results 
Inogen Appoints COO Andy Reding As President, CEO, Succeeding Kevin Smith 
Inogen Announces Leadership Transition 
Full Transcript: Inogen Q2 2026 Earnings Call 
12 Health Care Stocks Moving In Thursday's Intraday Session
Your note
Sign in to keep a note on INGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOEHNLEIN GLENN S | Director | Stock Award(Grant) | Jun 4, 2024 | 46,273 |
| GLEZER STANISLAV | Officer | Conversion of Exercise of derivative security | Apr 30, 2024 | 32,049 |
| KING KEVIN M | Director | Stock Award(Grant) | Jun 4, 2024 | 46,273 |
| LADONE MARY KAY | Director | Stock Award(Grant) | Jun 4, 2024 | 46,273 |
| MORA ELIZABETH A | Director | Stock Award(Grant) | Jun 4, 2024 | 48,568 |
| RAMADE GREGOIRE | Officer | Conversion of Exercise of derivative security | Nov 28, 2024 | 18,623 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Camber Capital Management LP | 8.40% | 2,000,000 | 16.86M | Sep 29, 2024 |
| Blackrock Inc. | 7.30% | 1,738,651 | 14.66M | Sep 29, 2024 |
| Brown Capital Management, LLC | 6.54% | 1,558,458 | 13.14M | Sep 29, 2024 |
| Vanguard Group Inc | 6.29% | 1,498,656 | 12.63M | Sep 29, 2024 |
| Divisadero Street Capital Management, LP | 4.44% | 1,056,403 | 8.91M | Sep 29, 2024 |
| JP Morgan Chase & Company | 3.76% | 896,106 | 7.55M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.08% | 733,584 | 6.18M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.62% | 624,722 | 5.27M | Oct 30, 2024 |
| Columbia Fds Ser Tr I-Columbia Small Cap Value Fd I | 2.08% | 496,308 | 4.18M | Jul 30, 2024 |
| Bridgeway Funds Inc-Small Cap Value Fund | 1.81% | 430,179 | 3.63M | Sep 29, 2024 |
| Brown Capital Management Small Company Fund | 1.74% | 415,484 | 3.50M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.49% | 354,264 | 2.99M | Sep 29, 2024 |